B Cell Prolymphocytic Leukemia - 14 Studies Found
Not yet recruiting |
: Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma :
|
Recruiting |
: Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies :
|
Withdrawn |
: Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML :
: 2014-08-28 : Drug: ZEN003365 |
Active, not recruiting |
: Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies : Leukemia : 2010-03-25 : Drug: Nelarabine Starting dose 200 mg/m2 for 5 day continuous infusion administered via a central cathet |